Somatropin Found Less Effective Than Somatrogon, a Long-Acting Human Growth Hormone Molecule, in Treatment of Growth Hormone Deficiency

 

Somatropin

Somatropin is a protein synthetic hormone that is commonly used in injecting it to the body to induce puberty. It is produced by the pituitary gland and the secretion of this hormone causes the enlargement of tissues and muscles. This hormone is found in higher levels during childhood and gradually decreases with the person's age. This allows the person to develop leaner and muscular muscles. It helps in improving bone strength and density and also helps in reducing fat.

Production of somatropin is stimulated by the secretion of the hormone receptor cells, which are present both in the anterior pituitary gland and the anterior suprachiasmatic nucleus. Somatropin or growth hormone, also called human growth hormone in its pure human form, is basically a peptide hormone, which stimulates cell growth, cell repair, and cell metabolism in humans and many other animals as well. It is therefore extremely important in human growth and development.

Somatropin has its own receptor called igf-1, which is present both in the anterior pituitary gland and the anterior suprachiasmatic nucleus. The hormone gets released from the pituitary gland into the bloodstream. It then travels to the brain where it passes through a complicated series of receptor binding steps before reaching the site of action. Here it releases its active ingredients or hormones, which cause changes in various cells and tissues in the body. The release of this hormone is timed by a particular body panel which includes the anterior pituitary gland, the anterior suprachiasmatic nucleus, and the brain. After releasing the hormones somatropin travels back to the pituitary gland where it is again processed and injected back into the body.

In recent studies, somatrogon, a long-acting human growth hormone (hGH) molecule, has shown more efficacy compared to somatropin in the treatment of pediatric patients with growth hormone deficiency. In February 2021, the European Medicines Agency validated for review the Marketing Authorization Application of Pfizer Inc., the U.S.-based pharmaceutical company, and OPKO Health Inc. for somatrogon, a long-acting recombinant human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency.


Comments

Popular posts from this blog

Light Linear Alpha Olefins Are Produces through Oligomerization of Ethylene and by Fischer-Tropsch Synthesis

Cervical Cancer Diagnostic Tests have become highly sophisticated with accurate diagnosis for effective treatment

Beta Glucan-based products have been shown to be effective in lowering cholesterol and preventing heart disease